MarketCapExport financials
Champions Oncology (CSBR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Champions Oncology Financial Ratios 2026-2010 | CSBR
Brief overview of Champions Oncology's financial ratios
The review covers five available annual periods spanning 2021 to 2025.
Market valuation is represented by P/E 22.52x (median 250.42x), P/S 1.86x (median 1.86x), P/B 28.07x (median 19.45x). Valuation is roughly 18.4% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.
Current earnings relative to valuation equal about 4.4% on the 1/P/E measure. This is a valuation reference, not an expected payout.
Current measures of operating quality are ROE 124.6%, ROA 14.5%, ROCE 120.7%. Returns on capital and assets point to efficient economics and a strong internal source of growth.
The cash return period is stable at 9.4 days initially and 1.9 days at the end.
What the ratios show
Champions Oncology's high-quality returns come with historically restrained multiples. Price appears more cautious than current business efficiency.
Annual Financial Ratios Champions Oncology
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-71.3 | 22.5 | -9.4 | -16.9 | 210.5 | 290.4 | -60.0 | 845.2 | -32.5 | -3.9 | -2.8 | -4.4 | -8.6 | -2.5 | -3.4 | -9.1 | - |
P/S |
1.4 | 1.9 | 1.4 | 1.7 | 2.3 | 2.6 | 3.7 | 4.0 | 2.4 | 1.7 | 2.6 | 6.5 | 5.5 | 1.9 | 4.1 | 5.0 | - |
EPS |
-0.1 | 0.3 | -0.5 | -0.4 | 0.0 | 0.0 | -0.2 | 0.0 | -0.1 | -0.6 | -1.2 | -2.2 | -0.1 | -0.1 | -0.2 | -0.1 | - |
EV (Enterprise Value) |
102 M | 125 M | 93.8 M | 110 M | 133 M | 121 M | 126 M | 114 M | 55.2 M | 31.2 M | 31.8 M | 52.1 M | 63.3 M | 10.1 M | 36.5 M | 36.8 M | -2.57 M |
EBITDA per Share |
0.02 | 0.45 | -0.4 | -0.23 | 0.16 | 0.1 | -0.09 | 0.0772 | -0.0903 | -0.605 | -1.17 | -1.5 | -1.08 | -2.03 | -2.3 | -1.71 | - |
EV/EBITDA |
391.8 | 20.3 | -17.2 | -34.8 | 62.9 | 77.0 | -164.4 | 119.8 | -47.4 | -3.6 | -2.6 | -3.7 | -9.5 | -1.0 | -2.7 | -4.7 | - |
PEG |
0.85 | -0.21 | 0.09 | 0.11 | -1.65 | -1.95 | 0.54 | 7.81 | -0.42 | -0.08 | -0.13 | 0.32 | -0.22 | -0.51 | 0.04 | 0.82 | - |
P/B |
20.6 | 28.1 | -36.0 | 19.5 | 12.7 | 14.2 | 22.3 | 48.3 | 15991.4 | 67.3 | 121.1 | 7.1 | 19.9 | 2.0 | -5.5 | 1822.0 | - |
P/CF |
-18.7 | 14.3 | -11.1 | 22.7 | 17.8 | -62.5 | 40.8 | 105.2 | -19.5 | -7.5 | -4.3 | -5.9 | -17.3 | -3.6 | -5.1 | -249.1 | - |
ROE % |
-29.83 | 124.63 | 382.34 | -115.08 | 6.02 | 4.87 | -38.73 | 5.72 | -49200.00 | -1721.00 | -4389.08 | -163.05 | -231.65 | -82.46 | 164.10 | -20010.53 | - |
ROA % |
-4.35 | 14.53 | -27.84 | -15.55 | 1.55 | 1.31 | -9.52 | 1.14 | -18.27 | -85.93 | -180.82 | -109.07 | -83.52 | -54.33 | -125.12 | -30.06 | - |
ROCE % |
-28.94 | 120.71 | 386.55 | -113.37 | 6.67 | 4.93 | -37.67 | 8.33 | -216.64 | -1207.27 | -2190.23 | -160.44 | -120.20 | -71.33 | -263.82 | -57.21 | - |
Current Ratio |
1.2 | 1.1 | 0.9 | 1.2 | 1.3 | 1.4 | 1.3 | 1.0 | 0.7 | 0.8 | 0.8 | 2.8 | 2.1 | 3.5 | 1.6 | 3.4 | - |
DSO |
74.9 | 66.4 | 63.8 | 59.4 | 61.3 | 52.3 | 52.0 | 59.0 | 70.6 | 53.9 | 42.8 | 43.7 | 41.9 | 21.9 | 29.8 | 58.4 | - |
DPO |
65.9 | 64.6 | 69.1 | 50.7 | 36.8 | 42.8 | 63.8 | 71.8 | 74.5 | 69.7 | 79.7 | 67.6 | 57.2 | 82.5 | 124.9 | 183.5 | - |
Operating Cycle |
74.9 | 66.4 | 63.8 | 59.4 | 61.3 | 52.3 | 52.0 | 59.0 | 70.6 | 53.9 | 42.8 | 43.7 | 41.9 | 21.9 | 29.8 | 58.4 | - |
Cash Conversion Cycle |
9.0 | 1.8 | -5.3 | 8.7 | 24.5 | 9.4 | -11.9 | -12.8 | -3.9 | -15.8 | -36.8 | -24.0 | -15.3 | -60.6 | -95.1 | -125.1 | - |
All numbers in USD currency
Quarterly Financial Ratios Champions Oncology
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.02 | 0.02 | -0.03 | -0.02 | 0.33 | -0.03 | - | 0.33 | 0.05 | 0.1 | - | -0.15 | -0.19 | - | 0.06 | - | -0.02 | - | 0.07 | 0.02 | 0.01 | - | 0.03 | - | - | 0.01 | -0.03 | 0.03 | 0.03 | -0.06 | -0.01 | 0.02 | 0.02 | 0.04 | -0.13 | -0.01 | -0.06 | - | -0.28 | -0.05 | -0.05 | -0.26 | -0.51 | -0.29 | -0.63 | - | -0.01 | -0.55 | -0.05 | - | -0.02 | -0.03 | -0.07 | -0.03 | -0.04 | -0.04 | -0.04 | -0.03 | -0.01 | -0.05 | -0.05 | -0.04 |
EBITDA per Share |
- | 0.04 | -0.01 | - | 0.36 | -0.01 | - | 0.36 | 0.08 | 0.13 | - | -0.11 | -0.16 | - | 0.09 | 0.04 | 0.02 | - | 0.09 | 0.05 | 0.06 | - | 0.05 | 0.02 | 0.02 | 0.02 | -0.02 | 0.06 | 0.06 | -0.04 | - | 0.05 | 0.05 | 0.05 | -0.12 | 0.01 | 0.01 | -0.05 | -0.27 | -0.03 | -0.04 | -0.25 | -0.6 | -0.27 | -0.28 | -0.33 | -0.02 | -0.63 | -0.05 | -0.05 | -0.01 | -0.02 | - | - | -0.04 | - | -0.04 | -0.03 | - | -0.05 | -0.05 | -0.06 |
ROE % |
-19.03 | 69.67 | 50.82 | 145.44 | 258.85 | -218.82 | -206.39 | -2433.27 | -2650.30 | -2748.68 | -2353.20 | -2353.37 | -130.04 | 4.80 | 16.66 | 11.57 | 13.13 | 16.68 | 14.40 | 3.90 | 0.49 | -0.89 | 2.75 | -14.50 | 0.01 | 14.52 | -23.94 | -24.15 | -25.27 | -26.39 | 90.77 | 37.81 | -0.79 | -46.72 | -295.33 | -333.05 | -323.58 | -306.92 | -1208.32 | -1033.58 | -1079.97 | -1107.26 | -73.47 | -154.22 | 73.56 | -584.42 | -659.25 | -633.43 | -780.90 | -58.49 | 76.70 | 114.54 | 123.82 | 136.37 | 137.22 | 184.77 | 394.09 | -10360.78 | -10385.85 | 98.41 | 236.79 | -10721.05 |
ROA % |
-2.50 | 13.16 | 10.84 | 15.15 | 21.40 | -0.60 | 0.83 | 0.83 | -7.75 | -8.29 | -13.56 | -13.60 | -7.21 | 1.37 | 5.17 | 3.77 | 4.19 | 5.12 | 4.49 | 1.19 | 0.25 | -0.12 | 0.87 | -3.01 | -0.81 | 1.48 | -4.57 | -2.26 | -1.86 | -0.97 | 10.69 | -6.91 | -10.97 | -15.61 | -29.99 | -45.08 | -49.90 | -54.87 | -90.53 | -156.17 | -183.51 | -202.96 | -183.06 | -89.14 | -148.50 | -176.83 | -192.67 | -194.79 | -123.90 | -91.42 | -70.54 | -82.32 | -106.97 | -123.61 | -123.59 | -128.00 | -101.18 | -78.92 | -59.80 | -23.79 | -19.91 | -16.10 |
ROCE % |
-23.47 | 65.23 | 45.77 | 143.06 | 256.99 | -225.57 | -210.55 | -2312.70 | -2529.07 | -2627.57 | -2227.27 | -2227.19 | -128.20 | 5.90 | 18.05 | 12.32 | 13.41 | 16.57 | 24.42 | 12.38 | 9.22 | 8.06 | 8.49 | -15.29 | -1.63 | 12.04 | -23.93 | -22.20 | -22.16 | -22.12 | 93.32 | 38.83 | 6.26 | -31.68 | -266.33 | -302.70 | -299.32 | -290.70 | -1196.04 | -1008.48 | -1053.88 | -1080.59 | -56.45 | -170.34 | 87.74 | -705.10 | -785.80 | -744.94 | -928.90 | -78.21 | 46.75 | 89.74 | 103.06 | 120.27 | 142.25 | 193.23 | 415.45 | -11270.01 | -11300.31 | 103.44 | 248.89 | -11652.63 |
Current Ratio |
1.2 | 1.2 | 1.1 | 1.2 | 1.2 | 1.1 | 1.1 | - | 1.0 | 1.0 | 0.9 | 1.0 | 1.1 | 1.2 | 1.4 | 1.3 | 1.4 | 1.4 | 1.5 | 1.4 | 1.4 | 1.4 | 1.3 | 1.4 | 1.3 | 1.3 | 1.3 | 1.2 | 1.1 | 1.2 | 1.1 | 1.2 | 1.1 | 1.0 | 1.4 | 1.1 | 1.1 | 1.1 | 1.5 | 1.7 | 1.7 | 1.0 | 0.4 | 2.2 | 2.5 | 3.0 | 1.8 | 0.6 | 1.1 | 1.6 | 3.5 | 1.6 | 2.3 | 2.9 | 2.2 | 1.3 | 1.8 | 1.7 | - | 2.4 | 2.5 | 2.8 |
DSO |
65.0 | 63.8 | 70.2 | 76.7 | 67.6 | 67.4 | - | 28.0 | 66.0 | 60.2 | - | 65.7 | 61.6 | - | 62.5 | 58.5 | 62.6 | 52.6 | 49.5 | 2622.7 | -3904.4 | - | 52.9 | 49.6 | 44.2 | 41.5 | 55.6 | 46.7 | 56.0 | - | 68.6 | 57.8 | 56.3 | 43.6 | - | 46.0 | 44.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2888.1 | - | - | - | - | 4154.2 | - |
DPO |
60.5 | 68.1 | 60.3 | 55.9 | 68.5 | 51.9 | - | 33.5 | 62.0 | 71.2 | - | 71.0 | 65.9 | - | 59.5 | 43.8 | 35.0 | - | 51.5 | 55.5 | 21.7 | - | 65.0 | 53.5 | 47.0 | 44.9 | 65.2 | 64.8 | 65.0 | 58.0 | 73.5 | 54.7 | 56.5 | 51.5 | - | 56.4 | 61.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 59.4 | - | 67.4 | - | - | 66.0 | 60.2 | - | 65.7 | 61.6 | - | 62.5 | 58.5 | 62.6 | 52.6 | 49.5 | 2622.7 | -3904.4 | - | 52.9 | 49.6 | 44.2 | 41.5 | 55.6 | 46.7 | 56.0 | - | 68.6 | 57.8 | 56.3 | 43.6 | - | 46.0 | 44.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2888.1 | - | - | - | - | 4154.2 | - |
Cash Conversion Cycle |
- | - | - | 4.8 | - | 15.5 | - | - | 4.0 | -11.0 | - | -5.2 | -4.3 | - | 3.1 | 14.7 | 27.7 | 52.6 | -2.0 | 2567.2 | -3926.1 | - | -12.1 | -3.9 | -2.8 | -3.4 | -9.6 | -18.1 | -9.0 | -58.0 | -4.8 | 3.0 | -0.2 | -7.9 | - | -10.4 | -17.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2888.1 | - | - | - | - | 4154.2 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Champions Oncology, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
